Immune signs of fatty liver disease in people with type 1 diabetes
Looks for immune differences linked to fatty liver disease in adults with type 1 diabetes.
Plain-language title generated from the registry record
Registry title: Immunological Signatures of MASLD and MASH in Patients With Type 1 Diabetes
Key facts
- Where
- Paris, FranceSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with type 1 diabetes who have a FibroScan liver exam planned during a day hospital visit. Adults with type 2 diabetes from an earlier cohort serve as the comparison group.
- Age
- Over 18 years
- Sex
- Men and women
- Disease stage
- Type 1 diabetes with a FibroScan scheduled during a day hospital visit, or type 2 diabetes in the comparison group.
- Earlier treatment
- People with type 2 diabetes must have taken part in the AngioSafe T2D cohort before. No other prior treatment is named.
Main reasons for not taking part
- Another long-lasting inflammatory disease (for example psoriasis, sarcoidosis, rheumatoid arthritis, inflammatory bowel disease)
- A condition that affects the immune system (cancer, blood cancers, HIV)
- Sudden signs of inflammation in blood tests at the day hospital visit (CRP > 10 mg/L; white blood cell count > 12 G/L)
- Having said no to taking part or to the reuse of their data
Read by machine on 11 November 2026.
Where in France
- Hospital, AP-HP, 2 rue Ambroise Paré, Paris, France (coordinating center) - Department of Diabetology, Bichat Hospital, AP-HP, 46 Rue Henri Huchard, Paris, FranceParis, FranceNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Assistance Publique - Hôpitaux de Paris
- Trial code
- NCT07927647
- Record updated
- 10 November 2026
- Original description
MASLD and its inflammatory form, MASH, are major public health concerns due to their high prevalence and association with hepatic and cardiovascular morbidity and mortality. Although extensively studied in type 2 diabetes (T2D), their pathophysiology in type 1 diabetes (T1D) remains poorly understood. Given the differences in immune mechanisms between T1D, primarily involving adaptive immunity, and T2D, associated with chronic innate immune activation, MASH may involve distinct immunoinflammatory pathways depending on the type of diabetes. This cross-sectional study aims to identify specific immunological and transcriptomic signatures associated with MASLD/MASH in patients with T1D and compare them with those observed in T2D, ultimately improving understanding of disease mechanisms and hepatic and cardiovascular risk stratification.Read full original descriptionShow less
Immunological Signatures of MASLD and MASH in Patients With Type 1 Diabetes
MASLD and its inflammatory form, MASH, are major public health concerns due to their high prevalence and association with hepatic and cardiovascular morbidity and mortality. Although extensively studied in type 2 diabetes (T2D), their pathophysiology in type 1 diabetes (T1D) remains poorly understood. Given the differences in immune mechanisms between T1D, primarily involving adaptive immunity, and T2D, associated with chronic innate immune activation, MASH may involve distinct immunoinflammatory pathways depending on the type of diabetes. This cross-sectional study aims to identify specific immunological and transcriptomic signatures associated with MASLD/MASH in patients with T1D and compare them with those observed in T2D, ultimately improving understanding of disease mechanisms and hepatic and cardiovascular risk stratification.
Inclusion: Male or female subject aged > 18 years; Subject living with type 1 diabetes (T1D) in the study arm, with a FibroScan examination scheduled during a day hospital (DH) visit; Subject living with type 2 diabetes (T2D) who has previously participated in the AngioSafe T2D cohort, in the control arm; Subject who verbally agrees to participate in the study (i.e., expresses no objection), after having been informed and given a reasonable period for consideration.
Exclusion: Subject with another chronic inflammatory disease (such as psoriasis, sarcoidosis, rheumatoid arthritis, inflammatory bowel disease, etc.); Subject with conditions affecting the immune system (cancer, hematological malignancies, HIV); Subject with an acute biological inflammatory syndrome (CRP > 10 mg/L; leukocyte count > 12 G/L) during the day hospital (DH) visit; Subject who has expressed opposition to participation in the study or to the reuse of their data.